{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-099333","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2024-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.218648+00:00","generated_at":"2026-05-29T22:55:53.687698+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aldeyra's reproxalap NDA accepted by FDA with April 2, 2025 PDUFA; expands AbbVie option deal","bullets":["FDA accepted resubmitted NDA for reproxalap for dry eye disease; PDUFA date April 2, 2025.","Expanded option with AbbVie: upon exercise, AbbVie pays $100M upfront (less $6M fees) plus up to $300M milestones.","If option exercised, profit/loss split 60% AbbVie, 40% Aldeyra; Aldeyra pre-commercial costs 60% reimbursed by AbbVie.","Option exercise period amended to 10 business days after FDA approval of reproxalap for dry eye disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-099333","json":"https://secwatch.observer/filing/0001213900-24-099333.json","markdown":"https://secwatch.observer/filing/0001213900-24-099333.md","text":"https://secwatch.observer/filing/0001213900-24-099333.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024099333/0001213900-24-099333-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024099333/ea0221568-8k_aldeyra.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:55:53.687698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}